Lilly breaks ground in Pennsylvania’s Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020
Facility will manufacture injectable medicines, including retatrutide Site will create 850 high-wage jobs and 2,000 construction jobsINDIANAPOLIS, Nov. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today broke ground on a $3.5 billion manufacturing…
